Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지

Association between Pax8-PPARγ1 Rearrangement and Follicular Thyroid Cancer: a Meta-Analysis

  • Li, Hang-Yu (Undergraduate of School of Public Health, Hebei Medical University) ;
  • Xie, Zhi-Hao (Undergraduate of School of Public Health, Hebei Medical University) ;
  • Xu, Cong-Hui (Undergraduate of School of Public Health, Hebei Medical University) ;
  • Pu, Mei-Ling (Undergraduate of School of Public Health, Hebei Medical University) ;
  • Chen, Zi-Yan (Undergraduate of School of Basic Medicine College, Hebei Medical University) ;
  • Yu, Miao (Undergraduate of School of Basic Medicine College, Hebei Medical University) ;
  • Wang, Heng-Shu (Department of Pathology, The Second Hospital of Hebei Medical University) ;
  • Zhou, Chen-Ming (Department of Electronic Microscopy Center, Key Laboratory of Immune Mechanism and Intervention on Serious Disease, Basic Medical College, Hebei Medical University) ;
  • Pu, Chao-Yu (Department of Nuclear Medicine, The General Hospital of Chinese People's Armed Police Force) ;
  • Liu, Wei (Department of Immunology, Key Laboratory of Immune Mechanism and Intervention on Serious Disease, Basic Medical College, Hebei Medical University)
  • Published : 2016.09.01
⟨ Previous Next ⟩

Abstract

Background: Pax8 and peroxisome proliferator-activated receptor gamma 1 gene (Pax8-$PPAR{\gamma}1$) are important factors in tumors. Several studies have suggested that follicular thyroid cancer may arise from Pax8- $PPAR{\gamma}1$ rearrangement. In order to have a better understanding of the association between Pax8-$PPAR{\gamma}1$ rearrangement and follicular thyroid cancer, we conducted the presenmt meta-analysis. Materials and Methods: The information was extracted from PubMed, EMBASE and Web of Science. Statistic analysis was performed with Stata12.0 software. Odds ratios (ORs) were calculated using a fixed-effects model. We also performed heterogeneity and publication bias analyses. Results: Nine studies including 198 follicular thyroid cancer patients and 268 controls were considered eligible. The frequency of Pax8-$PPAR{\gamma}1$ rearrangement was significantly higher in the follicular thyroid cancer group than in the control group, with a pooled OR of 6.63 (95%CI=3.50-12.7). In addition, through subgroup analysis, the OR between Pax8-$PPAR{\gamma}1$ rearrangement and follicular thyroid cancer was 6.04 (95%CI = 3.18-11.5) when using benign tumor tissues as controls. The OR for the method subgroup was 9.99 (95% CI =4.86-20.5) in the RT-PCR. Conclusions: The final results demonstrated that Pax8-$PPAR{\gamma}1$ rearrangement has significant association with follicular thyroid cancer.

Keywords

References

  1. Banito A, Pinto AE, Espadinha C, et al (2007). Aneuploidy and RAS mutations are mutually exclusive events in the development of well-differentiated thyroid follicular tumours. Clin Endocrinol (Oxf), 67, 706-11. https://doi.org/10.1111/j.1365-2265.2007.02949.x
  2. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. https://doi.org/10.2307/2533446
  3. Boos LA, Dettmer M, Schmitt A, et al (2013). Diagnostic and prognostic implications of the PAX8-PPARgamma translocation in thyroid carcinomas-a TMA-based study of 226 cases. Histopathol, 63, 234-41. https://doi.org/10.1111/his.12150
  4. Castro P, Rebocho AP, Soares RJ, et al (2006). PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab, 91, 213-20.
  5. Castro P, Roque L, Magalhaes J, et al (2005). A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol, 13, 235-8. https://doi.org/10.1177/106689690501300301
  6. Cheung L, Messina M, Gill A, et al (2003). Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 88, 354-7. https://doi.org/10.1210/jc.2002-021020
  7. Dwight T, Thoppe SR, Foukakis T, et al (2003). Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab, 88, 4440-5. https://doi.org/10.1210/jc.2002-021690
  8. Eberhardt NL, Grebe SK, McIver B, et al (2010). The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol, 321, 50-56. https://doi.org/10.1016/j.mce.2009.10.013
  9. Kroll TG, Sarraf P, Pecciarini L, et al (2000). PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science, 289, 1357-60. https://doi.org/10.1126/science.289.5483.1357
  10. Lacroix L, Lazar V, Michiels S, et al (2005). Follicular thyroid tumors with the PAX8-PPARgamma1 rearrangement display characteristic genetic alterations. Am J Pathol, 167, 223-31. https://doi.org/10.1016/S0002-9440(10)62967-7
  11. Lacroix L, Mian C, Barrier T, et al (2004). PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. Eur J Endocrinol, 151, 367-74. https://doi.org/10.1530/eje.0.1510367
  12. Marques AR, Espadinha C, Catarino AL, et al (2002). Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab, 87, 3947-52.
  13. Nikiforova MN, Biddinger PW, Caudill CM, et al (2002). PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol, 26, 1016-23. https://doi.org/10.1097/00000478-200208000-00006
  14. Pacini F, Schlumberger M, Dralle H, et al (2006). European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol, 154, 787-803. https://doi.org/10.1530/eje.1.02158
  15. Papadopoulou F, Efthimiou E (2009). Thyroid cancer after external or internal ionizing irradiation. Hell J Nucl Med, 12, 266-70.
  16. Peters JL, Sutton AJ, Jones DR, et al (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676-80. https://doi.org/10.1001/jama.295.6.676
  17. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-5. https://doi.org/10.1007/s10654-010-9491-z